224 related articles for article (PubMed ID: 22573627)
1. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease.
Ondo WG; Kenney C; Sullivan K; Davidson A; Hunter C; Jahan I; McCombs A; Miller A; Zesiewicz TA
Neurology; 2012 May; 78(21):1650-4. PubMed ID: 22573627
[TBL] [Abstract][Full Text] [Related]
2. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation.
Johanson JF; Morton D; Geenen J; Ueno R
Am J Gastroenterol; 2008 Jan; 103(1):170-7. PubMed ID: 17916109
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies.
Drossman DA; Chey WD; Johanson JF; Fass R; Scott C; Panas R; Ueno R
Aliment Pharmacol Ther; 2009 Feb; 29(3):329-41. PubMed ID: 19006537
[TBL] [Abstract][Full Text] [Related]
4. Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study.
Zangaglia R; Martignoni E; Glorioso M; Ossola M; Riboldazzi G; Calandrella D; Brunetti G; Pacchetti C
Mov Disord; 2007 Jul; 22(9):1239-44. PubMed ID: 17566120
[TBL] [Abstract][Full Text] [Related]
5. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety.
Johanson JF; Ueno R
Aliment Pharmacol Ther; 2007 Jun; 25(11):1351-61. PubMed ID: 17509103
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation.
Johanson JF; Drossman DA; Panas R; Wahle A; Ueno R
Aliment Pharmacol Ther; 2008 Apr; 27(8):685-96. PubMed ID: 18248656
[TBL] [Abstract][Full Text] [Related]
7. Lubiprostone: chloride channel activator for chronic constipation.
Rivkin A; Chagan L
Clin Ther; 2006 Dec; 28(12):2008-21. PubMed ID: 17296458
[TBL] [Abstract][Full Text] [Related]
8. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease.
Ondo WG; Tintner R; Voung KD; Lai D; Ringholz G
Mov Disord; 2005 Aug; 20(8):958-63. PubMed ID: 15800937
[TBL] [Abstract][Full Text] [Related]
9. A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain.
Jamal MM; Adams AB; Jansen JP; Webster LR
Am J Gastroenterol; 2015 May; 110(5):725-32. PubMed ID: 25916220
[TBL] [Abstract][Full Text] [Related]
10. Lubiprostone vs Senna in postoperative orthopedic surgery patients with opioid-induced constipation: a double-blind, active-comparator trial.
Marciniak CM; Toledo S; Lee J; Jesselson M; Bateman J; Grover B; Tierny J
World J Gastroenterol; 2014 Nov; 20(43):16323-33. PubMed ID: 25473191
[TBL] [Abstract][Full Text] [Related]
11. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study.
Okun MS; Fernandez HH; Rodriguez RL; Romrell J; Suelter M; Munson S; Louis ED; Mulligan T; Foster PS; Shenal BV; Armaghani SJ; Jacobson C; Wu S; Crucian G
Arch Neurol; 2006 May; 63(5):729-35. PubMed ID: 16682542
[TBL] [Abstract][Full Text] [Related]
12. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.
Hauser RA; Schapira AH; Rascol O; Barone P; Mizuno Y; Salin L; Haaksma M; Juhel N; Poewe W
Mov Disord; 2010 Nov; 25(15):2542-9. PubMed ID: 20669317
[TBL] [Abstract][Full Text] [Related]
14. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.
Stern MB; Marek KL; Friedman J; Hauser RA; LeWitt PA; Tarsy D; Olanow CW
Mov Disord; 2004 Aug; 19(8):916-23. PubMed ID: 15300656
[TBL] [Abstract][Full Text] [Related]
15. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
17. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
Parkinson Study Group
Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
[TBL] [Abstract][Full Text] [Related]
18. Lubiprostone for constipation in adults with cystic fibrosis: a pilot study.
O'Brien CE; Anderson PJ; Stowe CD
Ann Pharmacother; 2011 Sep; 45(9):1061-6. PubMed ID: 21852592
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial.
Emkey R; Rosenthal N; Wu SC; Jordan D; Kamin M;
J Rheumatol; 2004 Jan; 31(1):150-6. PubMed ID: 14705234
[TBL] [Abstract][Full Text] [Related]
20. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
Peniston JH; Gould E
Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
